Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 1 · 33.3%

Chemotherapy with TKI vs chemotherapy alone

Progression‐free survival · recurrent platinum‐resistant EOC

Chemotherapy with TKI may leads to lower progression‐free survival (PFS) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.7 [0.55, 0.89]
8 studies · 940 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.56 [0.44, 0.72]
1 study · 282 participants
Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Progression‐free survival · recurrent EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) leads to lower progression‐free survival (PFS) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.73 [0.65, 0.82]
3 studies · 1250 participants
High